Loading...
Market
Will Bristol Myers Squibb's stock price outperform, underperform, or match its competitors in Q4 2024?
5
Resolution / Starting Odds
Outperform • 33%
Underperform • 33%
Match • 33%
Stock market performance data from credible financial sources such as Yahoo Finance or Bloomberg
Story
FDA Approves Bristol Myers' Breyanzi (Liso-Cel) for Relapsed Mantle Cell Lymphoma, Third Approval This Year
May 30, 2024, 07:25 PM
The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Breyanzi, also known as Liso-Cel, a CAR T cell therapy, for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) after two lines of therapy. This approval, announced on Thursday, marks the third time this year that the FDA has expanded the use of Breyanzi for treating aggressive and rare types of blood cancer.
View original story
Similar markets
Increase in sales • 33%
Decrease in sales • 33%
No significant change • 34%
Outperform • 33%
Match • 33%
Underperform • 33%
Underperform • 33%
Match • 34%
Outperform • 33%
Outperforms • 25%
Underperforms • 25%
Matches • 25%
Data Inconclusive • 25%
Outperform S&P 500 • 33%
Match S&P 500 • 33%
Underperform S&P 500 • 33%
Increase over 200% • 25%
Increase 100-200% • 25%
Increase up to 100% • 25%
Decrease or no change • 25%
Outperform S&P 500 • 33%
Match S&P 500 performance • 33%
Underperform S&P 500 • 33%